Q-omics provides the consensus-scored STX18 profile across patient tissues and cancer cell-line models. STX18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, STX18 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, STX18 RNA expression shows 19,598 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, KIRC, and ACC as cancer lineages where STX18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX18 survival associations across molecular data types. STX18 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX18 RNA expression–survival associations across cancer types. High STX18 expression shows unfavorable associations in UVM, LUAD, LIHC and ACC, but favorable associations in UCEC and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for STX18 RNA expression.
This table summarizes STX18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STX18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX18 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LIHC, STAD, COAD and BLCA. The KIRC box plot shows higher STX18 RNA expression in normal versus tumor tissue (log2 FC = −0.692, t-test p < 0.001).
This table shows molecular features associated with STX18 in patient tissues and cancer cell lines. In patient samples, STX18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STX18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
